RU2001115133A - Composition for the treatment of cancer and method of using natural vegetable oils - Google Patents

Composition for the treatment of cancer and method of using natural vegetable oils

Info

Publication number
RU2001115133A
RU2001115133A RU2001115133/14A RU2001115133A RU2001115133A RU 2001115133 A RU2001115133 A RU 2001115133A RU 2001115133/14 A RU2001115133/14 A RU 2001115133/14A RU 2001115133 A RU2001115133 A RU 2001115133A RU 2001115133 A RU2001115133 A RU 2001115133A
Authority
RU
Russia
Prior art keywords
pharmaceutical composition
composition according
compound
essential oil
butyltin
Prior art date
Application number
RU2001115133/14A
Other languages
Russian (ru)
Other versions
RU2252772C2 (en
Inventor
Стивен М. БЕССЕТ
Иссем И. ИНЕМ
Original Assignee
Экосмарт Текнолоджиз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Экосмарт Текнолоджиз, Инк. filed Critical Экосмарт Текнолоджиз, Инк.
Publication of RU2001115133A publication Critical patent/RU2001115133A/en
Application granted granted Critical
Publication of RU2252772C2 publication Critical patent/RU2252772C2/en

Links

Claims (14)

1. Фармацевтический состав для предотвращения или лечения рака мягких тканей у млекопитающих, содержащий, по крайней мере, одно соединение растительных эфирных масел.1. A pharmaceutical composition for the prevention or treatment of soft tissue cancer in mammals, comprising at least one compound of vegetable essential oils. 2. Фармацевтический состав по п.1, отличающийся тем, что указанное соединение растительных эфирных масел выбирают из группы, включающей альдегид С16 (чистый), амилокоричный альдегид, амилсалицилат, анисовый альдегид, бензиловый спирт, бензилацетат, циннамаль, коричный спирт, α-терпинеол, карвакрол, карвеол, цитраль, цитронеллаль, цинтронеллол, п-кумен, диэтилфталат, диметилсалицилат, дипропиленгликоль, эвкалиптол (цинеол), эвгенол, изоэвгенол, галаксолид, гераниол, гваякол, ионон, d-лимонен, ментол, метилантранилат, метилионон, метилсалицилат, α-фелландрен, масло кудрявой мяты, периллальдегид, 1- или 2-фенилэтиловый спирт, 1- или 2-фенилэтилпропионат, пиперональ, пиперонилацетат, пиперониловый спирт, D-пулегон, терпинен-4-ол, терпинилацетат, 4-трет-бутилциклогексилацетат, тимьяновое масло, тимол, метаболиты транс-анетола, ванилин и этилванилин.2. The pharmaceutical composition according to claim 1, characterized in that said compound of vegetable essential oils is selected from the group consisting of C16 aldehyde (pure), amilocinnamic aldehyde, amyl salicylate, anisic aldehyde, benzyl alcohol, benzyl acetate, cinnamal, cinnamon alcohol, α-terpineol , carvacrol, carveol, citral, citronellal, cintronellol, p-cumene, diethyl phthalate, dimethyl salicylate, dipropylene glycol, eucalyptol (cineole), eugenol, isoeuvgenol, galaxolide, geraniol, guaiacol, ionone, d-methylononate, m-alkylene, m-fellandren, spearmint oil, perillaldehyde, 1- or 2-phenylethyl alcohol, 1- or 2-phenylethyl propionate, piperonal, piperonyl acetate, piperonyl alcohol, D-pulugon, terpinene-4-ol, terpinyl acetate, 4-tert-butyltin-butyltin-butyltin-butyltin-butyltin-butyltin-butyltin-butyltinbutyl acetate oil, thymol, metabolites of trans-anetole, vanillin and ethyl vanillin. 3. Фармацевтический состав по п.1, содержащий, кроме того, фармацевтически приемлемый носитель.3. The pharmaceutical composition according to claim 1, further comprising a pharmaceutically acceptable carrier. 4. Фармацевтический состав по п.1, отличающийся тем, что указанный рак мягких тканей представляет собой рак молочной железы.4. The pharmaceutical composition according to claim 1, characterized in that said soft tissue cancer is breast cancer. 5. Фармацевтический состав по п.1, отличающийся тем, что указанным соединением растительного эфирного масла является эвгенол.5. The pharmaceutical composition according to claim 1, characterized in that the said compound of the vegetable essential oil is eugenol. 6. Фармацевтический состав по п.1, отличающийся тем, что указанным соединением растительного эфирного масла является тимол.6. The pharmaceutical composition according to claim 1, characterized in that said compound of vegetable essential oil is thymol. 7. Фармацевтический состав по п.1, отличающийся тем, что указанным соединением растительного эфирного масла является изоэвгенол.7. The pharmaceutical composition according to claim 1, characterized in that said compound of vegetable essential oil is isoeugenol. 8. Фармацевтический состав по п.1, отличающийся тем, что указанным соединением растительного эфирного масла является бензиловый спирт.8. The pharmaceutical composition according to claim 1, characterized in that the said compound of vegetable essential oil is benzyl alcohol. 9. Фармацевтический состав по п.1, отличающийся тем, что указанным соединением растительного эфирного масла является карвакрол.9. The pharmaceutical composition according to claim 1, characterized in that said compound of the vegetable essential oil is carvacrol. 10. Фармацевтический состав по п.1, отличающийся тем, что указанным соединением растительного эфирного масла является коричный спирт.10. The pharmaceutical composition according to claim 1, characterized in that said compound of the plant essential oil is cinnamon. 11. Фармацевтический состав по п.1, отличающийся тем, что указанным соединением растительного эфирного масла является коричный альдегид.11. The pharmaceutical composition according to claim 1, characterized in that said compound of the plant essential oil is cinnamaldehyde. 12. Фармацевтический состав по п.1, отличающийся тем, что указанным соединением растительного эфирного масла является цитронеллаль.12. The pharmaceutical composition according to claim 1, characterized in that the said compound of vegetable essential oil is citronellal. 13. Фармацевтический состав по п.1, отличающийся тем, что указанным соединением растительного эфирного масла является транс-анетол.13. The pharmaceutical composition according to claim 1, characterized in that said compound of vegetable essential oil is trans-anethole. 14. Способ лечения рака, включающий введение нуждающемуся в этом пациенту терапевтически эффективное количество состава по п.1.14. A method of treating cancer, comprising administering to a patient in need thereof a therapeutically effective amount of a composition according to claim 1.
RU2001115133/15A 1998-12-07 1999-12-07 Composition for treating cancer and method for applying natural vegetable oils RU2252772C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11127198P 1998-12-07 1998-12-07
US60/111,271 1998-12-07

Publications (2)

Publication Number Publication Date
RU2001115133A true RU2001115133A (en) 2003-05-20
RU2252772C2 RU2252772C2 (en) 2005-05-27

Family

ID=22337523

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2001115133/15A RU2252772C2 (en) 1998-12-07 1999-12-07 Composition for treating cancer and method for applying natural vegetable oils

Country Status (24)

Country Link
US (8) US20020182268A1 (en)
EP (3) EP1137427A1 (en)
JP (3) JP2002531511A (en)
KR (1) KR20010080692A (en)
CN (1) CN100448454C (en)
AR (3) AR020019A1 (en)
AT (1) ATE307601T1 (en)
AU (3) AU2167000A (en)
BR (1) BR9916879A (en)
CA (3) CA2353475A1 (en)
CZ (1) CZ20011979A3 (en)
DE (1) DE69928000T2 (en)
ES (1) ES2247858T3 (en)
HU (1) HUP0104674A3 (en)
ID (1) ID29393A (en)
IL (1) IL143488A0 (en)
MX (3) MXPA01005641A (en)
NO (1) NO20012774L (en)
NZ (1) NZ527850A (en)
PL (1) PL349028A1 (en)
RU (1) RU2252772C2 (en)
TR (1) TR200101481T2 (en)
WO (3) WO2000033858A1 (en)
ZA (1) ZA200104611B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD2231C2 (en) * 2003-03-05 2004-02-29 Ион КАЛМЫК Composition for treatment of oncologic pathologies

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2353475A1 (en) * 1998-12-07 2000-06-15 Ecosmart Technologies, Inc. Cancer treatment composition and method using natural plant essential oils with signal transduction modulators
DE10113513A1 (en) * 2001-03-20 2002-10-02 Medinnova Ges Med Innovationen Drug combination of kinase inhibitor and neurotropic factor, useful for treating and/or preventing nerve and/or glial cell damage, e.g. associated with neurodegenerative diseases
US7186735B2 (en) * 2002-08-07 2007-03-06 Sanofi-Aventis Deutschland Gmbh Acylated arylcycloalkylamines and their use as pharmaceuticals
EP2387882A3 (en) * 2002-08-12 2012-10-31 Lonza Inc. Antimicrobial compositions comprising cinnamaldehyde
CA2407755A1 (en) * 2002-10-11 2004-04-11 The Hospital For Sick Children Inhibition of vegf secretion
DE10259619A1 (en) * 2002-12-18 2004-07-08 Metagen Pharmaceuticals Gmbh Use of a TRPM8 activating substance for tumor treatment
US20060263403A1 (en) * 2003-04-24 2006-11-23 Essam Enan Compositions and methods for controlling insects involving the tyramine receptor
US7541155B2 (en) 2003-04-24 2009-06-02 Tyratech, Inc. Methods of screening compositions for potential insect control activity
US7622269B2 (en) * 2004-03-19 2009-11-24 Tyratech, Inc. Methods of screening tyramine- and octopamine-expressing cells for compounds and compositions having potential insect control activity
JP5105873B2 (en) * 2003-07-02 2012-12-26 ジェネンテック， インコーポレイテッド TRP-P8 active compounds and therapeutic treatment methods
DE10341933A1 (en) * 2003-09-11 2005-04-14 Lts Lohmann Therapie-Systeme Ag Medicated skin patches containing essential oils for the treatment of colds and methods of making the same
SE0401302D0 (en) * 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Inhibition of recognized phosphorylation
WO2006120495A1 (en) * 2005-05-13 2006-11-16 Advanced Scientific Developements Pharmaceutical composition comprising an antiviral agent, an antitumour agent or an antiparasitic agent and an active substance selected from carveol, thymol, eugenol, borneol and carvacrol
US20090035403A2 (en) * 2005-06-16 2009-02-05 Mmi Corporation Novel anticancer agent, methods for obtaining the same and pharmaceutical compositions thereof
CN100553628C (en) 2005-08-25 2009-10-28 中国人民解放军军事医学科学院放射与辐射医学研究所 The application of 2-bromo-isovanillin in the anticancer and/or radiation of preparation, chemotherapy sensitizing medicine
EP2043620B1 (en) * 2006-06-27 2017-05-03 Tyratech, Inc. Compositions for use in treating a parasitic infections in a mammalian subject
CN101489377A (en) * 2006-07-17 2009-07-22 蒂拉德克公司 Compositions and methods for controlling insects
MX2009007637A (en) * 2007-01-16 2009-09-28 Tyratech Inc Pest control compositions and methods.
JP2011021013A (en) * 2009-06-19 2011-02-03 Ube Industries Ltd Method for producing aromatic methyl alcohol compound having oxyl group
EP2480090B1 (en) 2009-09-24 2013-11-06 Unilever NV Disinfecting agent comprising eugenol, terpineol and thymol
US8003393B1 (en) * 2010-02-09 2011-08-23 Panasonic Corporation Method for determining whether or not a mammal is affected with a lung cancer
WO2012006563A2 (en) 2010-07-08 2012-01-12 The Administrators Of The Tulane Educational Fund Novel daidzein analogs as treatment for cancer
FR2967055B1 (en) * 2010-11-08 2012-12-21 Biochimie Appliquee Solabia COSMETIC COMPOSITIONS BASED ON PIPERONYL ESTERS AND THEIR USE IN SOSMETICS AS ANTI-AGING SKIN AND DEPIGMENTING AGENT
EP2648681B1 (en) 2010-12-07 2015-01-07 Unilever N.V. An oral care composition
US9023888B2 (en) * 2011-02-02 2015-05-05 Max Reynolds Composition of monoterpenoids having bactericidal properties
WO2012177799A1 (en) * 2011-06-20 2012-12-27 Atheronova Operations, Inc. Subcutaneous fat reduction
WO2013064360A2 (en) 2011-11-03 2013-05-10 Unilever N.V. A personal cleaning composition
KR101357395B1 (en) 2012-08-06 2014-02-05 영남대학교 산학협력단 Novel tetrazolohydrazone derivative and parmaceutical composition for preventing or treating cancer containing thereof
WO2015102448A1 (en) * 2014-01-03 2015-07-09 전북대학교 산학협력단 Hybrid anticancer prodrug simultaneously producing cinnamaldehyde and quinone methide and method for preparing same
US9950071B2 (en) * 2014-01-03 2018-04-24 Industrial Cooperation Foundation Chonbuk National University Hybrid anticancer prodrug simultaneously producing cinnamaldehyde and quinone methide and method for preparing same
JP6669665B2 (en) * 2014-03-20 2020-03-18 ソシエテ・デ・プロデュイ・ネスレ・エス・アー Methods and compositions for using cinnamaldehyde and zinc for weight management
US10092550B2 (en) 2014-10-21 2018-10-09 Ions Pharmaceutical S.À R.L. Therapeutic compositions containing curcumin, harmine, and isovanillin components, and methods of use thereof
US20160106722A1 (en) 2014-10-21 2016-04-21 Life Plus, LLC Human therapeutic agents
US9907786B2 (en) 2014-10-21 2018-03-06 Ions Pharmaceutical S.À R.L. Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof
DE102015119552B4 (en) * 2015-10-23 2022-06-15 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Composition containing a monoterpene for the treatment of tumor and/or cancer diseases
CN105294465A (en) * 2015-12-08 2016-02-03 天津医科大学 Chiral ionone alkaloid derivative with breast cancer metastasis prevention function and medical application of chiral ionone alkaloid derivative
CN105559074B (en) * 2016-02-03 2019-02-12 华南农业大学 A kind of tealeaves volatile essential oil is preparing the application in cancer-preventing health product or anticancer drug
KR101798203B1 (en) 2016-09-23 2017-11-15 전북대학교 산학협력단 Hybrid anticancer prodrug for creating cinnam aldehyde with quinone metide by acidic pH and esterase, and method for preparing the same
CN112218620A (en) 2018-04-06 2021-01-12 优卡健康有限公司 Treatment of cancer by guanidine salt derivatives
CN109112106B (en) * 2018-09-07 2022-01-04 广州长峰生物技术有限公司 Method for establishing in vitro model of human primary liver cancer tissue
WO2022069013A1 (en) * 2020-10-04 2022-04-07 Omar Bencherguia Medicinal composition for the treatment and prevention of covid-19 and other infections and conditions. novel uses of alpha-acetoxytoluene, benzyl alcohol and benzyl groups for controlling the covid-19 pandemic and other infections and conditions

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261989A (en) * 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
JPS57106697A (en) * 1980-12-22 1982-07-02 Kyowa Hakko Kogyo Co Ltd Easily absorbable map composition and preparation containing the same
US4751224A (en) * 1983-07-21 1988-06-14 Brown University Research Foundation Treatment of metastasis
FR2557452B1 (en) * 1983-12-28 1986-08-14 Roussel Uclaf NOVEL COMPOSITIONS FOR SKIN CARE CONTAINING PRIMER OIL AND RATE TISSUE TRAITS
DE3515253C1 (en) * 1985-04-27 1986-06-19 Werner 6780 Pirmasens Walter Use of isopropanolic solutions of diphenyl as topical pharmaceutical
DE3634697A1 (en) * 1986-10-11 1988-04-21 Dentaire Ivoclar Ets DENTAL MATERIAL TO CONTROL CARIES AND PERIODONTOSE
DE3826846A1 (en) * 1988-08-06 1990-02-08 Goedecke Ag ALKOXY-4 (1H) -PYRIDONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS DRUGS
DE3829200A1 (en) * 1988-08-29 1990-03-01 Kaempgen Dieter Dr Phil Active compounds against the immunodeficiency disease AIDS
JP2746453B2 (en) * 1990-03-13 1998-05-06 鐘紡株式会社 Active oxygen scavenger
EP0650723A3 (en) 1990-03-23 1995-08-30 Nippon Kayaku Kk Novel pharmaceutical use of forskolin derivatives.
US5605930A (en) * 1991-10-21 1997-02-25 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for treating and preventing pathologies including cancer
FR2683454B1 (en) 1991-11-13 1995-06-09 Pf Medicament BACTERICIDAL PHARMACEUTICAL COMPOSITION.
DK0663831T3 (en) * 1991-12-13 1995-07-26 Searle & Co Transdermal azidothymidine
DE69304595T2 (en) * 1992-04-29 1997-01-23 Nordica Spa Braking device on roller skate
NZ252051A (en) * 1992-05-19 1996-10-28 Graham Edmund Kelly Health supplement comprising a phyto-oestrogen selected from genistein, daidzein, biochanin and/or formononetin
FR2697133B1 (en) * 1992-10-28 1995-01-13 Transbiotech Biocidal and / or biostatic composition and its applications.
US5602184A (en) 1993-03-03 1997-02-11 The United States Of America As Represented By Department Of Health And Human Services Monoterpenes, sesquiterpenes and diterpenes as cancer therapy
US5387584A (en) * 1993-04-07 1995-02-07 Pfizer Inc. Bicyclic ansamycins
JP3263481B2 (en) 1993-05-19 2002-03-04 三洋電機株式会社 Semiconductor device and method of manufacturing semiconductor device
FR2706771A1 (en) * 1993-06-21 1994-12-30 Pelletier Jacques Formula for the treatment of certain cancers.
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5626854A (en) 1994-03-17 1997-05-06 Kao Corporation Bath composition
US5911995A (en) * 1994-08-19 1999-06-15 Regents Of The University Of Minnesota EGF-genistein conjugates for the treatment of cancer
US5795910A (en) * 1994-10-28 1998-08-18 Cor Therapeutics, Inc. Method and compositions for inhibiting protein kinases
US6133312A (en) * 1997-03-04 2000-10-17 Wisconsin Alumni Research Foundation Method of suppressing tumor growth with combinations of isoprenoids and statins
AU7165798A (en) 1997-04-28 1998-11-24 Anticancer, Inc. Use of genistein and related compounds to treat certain sex hormone related conditions
JP2001510168A (en) * 1997-07-18 2001-07-31 ノボ ノルディスク アクティーゼルスカブ Use of FVIIa or FVIIai for the treatment of adverse conditions associated with FVIIa-mediated intracellular signaling pathway
JP2001506533A (en) * 1998-03-20 2001-05-22 ザ、プロクター、エンド、ギャンブル、カンパニー Composition for fragrance release
AT407821B (en) * 1998-03-24 2001-06-25 Franz Dr Stueckler MEDIUM BASED ON NATURAL SUBSTANCES
US6028061A (en) 1998-06-18 2000-02-22 Children's Medical Center Corp Angiogenesis inhibitors and use thereof
EP1123106B1 (en) * 1998-10-23 2003-07-23 Dieter Ebert Composition containing eugenol and polyphenols and use of such a composition for wound healing
KR100312622B1 (en) * 1998-11-03 2002-02-28 김송배 Stabilized anticancer composition mainly composed of herbal medicine and its manufacturing method
CA2353475A1 (en) * 1998-12-07 2000-06-15 Ecosmart Technologies, Inc. Cancer treatment composition and method using natural plant essential oils with signal transduction modulators
US6147107A (en) * 1998-12-20 2000-11-14 Virginia Commonwealth University Specific inhibition of the P42/44 mitogen activated protein (map) kinase cascade sensitizes tumor cells

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD2231C2 (en) * 2003-03-05 2004-02-29 Ион КАЛМЫК Composition for treatment of oncologic pathologies

Similar Documents

Publication Publication Date Title
RU2001115133A (en) Composition for the treatment of cancer and method of using natural vegetable oils
Uritu et al. Medicinal plants of the family Lamiaceae in pain therapy: A review
Banskota et al. Recent progress in pharmacological research of propolis
Shokrzadeh et al. The chemistry, pharmacology and clinical properties of Sambucus ebulus: A review
KR101431060B1 (en) Compositions of bakuchiol and methods of making the same
Banskota et al. Hepatoprotective and anti-Helicobacter pylori activities of constituents from Brazilian propolis
Ahuja et al. Apitherapy-A sweet approach to dental diseases. Part II: Propolis
Narayanan et al. Salvia officinalis in dentistry
Chan et al. Phytochemistry and pharmacology of three Piper species: An update
Singh et al. Hepatoprotective activity of indigtone—a bioactive fraction from Indigofera tinctoria Linn.
Farag et al. Salvadora persica L.: Toothbrush tree with health benefits and industrial applications–An updated evidence-based review
Kiany et al. Assessing the effect of pomegranate fruit seed extract mouthwash on dental plaque and gingival inflammation
KR101954118B1 (en) Bakuchiol compositions for treatment of post inflammatory hyperpigmentation
JP4789334B2 (en) Skin preparation for wrinkle improvement and prevention
JP2002255781A5 (en)
KR20190079291A (en) Cosmetic composition containing pseudo-ceramide originated from botanical oil
Wahjudi et al. Bidens pilosa Linn.: beautiful weed for the healthy mouth–a mini review
Amirtharaj et al. Evaluating the analgesic efficacy of Solanum surattense (Herbal Seed Extract) in relieving pulpal pain-an in-vivo study
US20170020946A1 (en) Analgesic compositions and methods of use
EP2892526A1 (en) Composition comprising licoricidine
JPH0458447B2 (en)
FR3063905A1 (en) USE OF COPAIFERA IN COSMETICS AND DERMATOLOGY
JPS60109516A (en) Composition for oral cavity
Rani et al. Ethnomedicinal, Pharmacological and Phytochemical Screening of Supari (Areca catechu Linn.): A Review
JP4392114B2 (en) Dermal collagen fiber bundle reconstituting agent and composition containing the same